Neoadjuvant Pazopanib in Renal Cell Carcinoma

Summary

This study will be a single arm phase II clinical trial of 8 weeks of daily, oral neo-adjuvant pazopanib prior to nephrectomy in 39 evaluable patients with histologically confirmed localized renal cell carcinoma (RCC).

Timeline

Start

2011-06

Primary completion

2015-01-07

Completion

2017-02-15

Drugs

Indications